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Globally, 1.7 million children are living with HIV, 90% in sub-Saharan Africa (SSA). The 
remarkable scale-up of combination antiretroviral therapy (ART) has resulted in escalating 
numbers of children with HIV (CWHIV) reaching adolescence. Unfortunately, in SSA, HIV 
diagnosis is often delayed with children starting ART late in childhood. In recent years, there 
have been increasing reports from low-income settings of CWHIV experiencing multisystem 
chronic comorbidities despite ART. Many of these chronic conditions show clinical 
phenotypes distinct from those in adults with HIV, and result in disability and reduced quality 
of life. In this review, we discuss the spectrum and pathogenesis of comorbidities among 
CWHIV in SSA. Prompt diagnosis and treatment of perinatally acquired HIV infection remains 
a priority. In addition, there is need for increased awareness of the burden of chronic 
comorbidities. Diagnostic and therapeutic strategies need to be developed if CWHIV are to 




















Introduction   
The HIV pandemic has been established for 40 years and worldwide 1.7 million children were 
living with HIV in 2018, 90% in sub-Saharan Africa (SSA). The vast majority have been 
infected by mother-to-child transmission.1 Due to the remarkable scale-up of effective 
prevention of mother-to-child transmission interventions, the number of perinatally-acquired 
HIV (PHIV) infections dropped from 280,000 in 2010 to 160,000 in 2018.1 At the same time 
over the past decade, access to combination antiretroviral therapy (ART) (a combination of 
three drugs leading to durable viral suppression) has expanded globally, resulting in a 
substantial decline in mortality rates and increased life-expectancy among children. Thus 
escalating numbers of children, who would previously have died in infancy and early childhood 
from untreated HIV infection are now surviving to adolescence.2 HIV has therefore changed 
from a life-threatening illness to a chronic, treatable, albeit incurable, condition.   
 
In adults with well-controlled HIV infection on ART in high-income countries, a range of 
comorbidities, including cardiovascular, renal, neurocognitive and lung disease, have been 
described and termed “non-AIDS-defining illnesses (NADIs)”. This is in contrast to the 
opportunistic infections and malignancies that occur at advanced stages of HIV disease as a 
consequence of HIV-mediated immunosuppression. Likewise, there is now increasing 
recognition that children with HIV (CWHIV), including those taking ART are also at risk of 
developing chronic multisystem comorbidities and concomitant disability.3,4 There have been 
reports from some settings of a trend from infectious events to non-infectious morbidities 
associated with inflammation, immunodeficiency and drug toxicity as CWHIV age.5   
 
Many of these comorbidities will be driven by underlying inflammation associated with HIV-
infection. The spectrum of morbidities in children may differ from those in adults, likely related 
to the timing of HIV infection and /or ART initiation and the absence of traditional adult risk 
factors such as ageing, smoking and alcohol use. Furthermore, there may be differences in the 
epidemiology of comorbidities in CWHIV in different settings. In high-income settings, 
combination ART became available in 1996, whereas in much of SSA paediatric ART was 
introduced after 2004. In addition, CWHIV in SSA start ART much later than those in high-
income settings. In a global meta-analysis of children who entered HIV care before ten years 
of age, the age at ART initiation among children in Africa was 7.8 years compared to 0.9 years 




In this review, we discuss the spectrum of chronic morbidities in children growing up with HIV 
focusing on studies in SSA, the likely pathogenesis underlying the development of 
comorbidities and the implications for HIV care and management and HIV programmes that 
have hitherto largely focused on ART delivery.   
 
Search strategy and selection criteria 
This is a descriptive review on comorbidities associated with HIV infection in children, 
informed by clinical experience and expert opinion. We searched PubMed for articles 
published from January 2014 to July 2019, with MeSH terms for HIV, Africa, children and 
adolescents, and with MeSH and related terms for specific topic areas (e.g. “cardiac disease”, 
“lung disease”). We also looked for relevant publications among our personal files. We did not 
set any language limits. Articles resulting from these searches and relevant references cited in 
those articles were reviewed. The final reference list was generated on the basis of relevance 
to the broad scope of this review. 
 
HIV-related chronic comorbidities 
Chronic lung disease  
While the incidence of acute pulmonary infections in CWHIV has declined due to 
cotrimoxazole prophylaxis and ART, several studies have reported a substantial burden of 
chronic respiratory symptoms and signs among children growing up with HIV taking ART 
including cough, breathlessness, reduced exercise tolerance and hypoxia,7-9 and reduced lung 
function predominantly airflow obstruction with little reversibility with bronchodilators.10-11 
This has been reported in the context of late initiation of ART in childhood.  High-resolution 
computed tomography studies (HRCT) show mosaic decreased attenuation as the predominant 
radiological finding with or without bronchiectasis (Figure 1A).12,13 Mosaic attenuation 
correlates strongly with reduced Forced Expiratory Volume in one second (FEV1), and 
together with hypoxia and irreversible airflow obstruction, these findings are consistent with 
constrictive obliterative bronchiolitis (OB).12 Notably, radiological findings consistent with 
lymphoid interstitial pneumonitis, the most common cause of chronic lung disease among 
CWHIV in the pre-ART era, have become rare in the ART era.12,14 OB is characterised by 
inflammation of the bronchiolar epithelium, leading to dense fibrous scarring with small airway 
obstruction, complicated by recurrent infections and bronchiectasis. It has been described 




and more commonly in the Southern hemisphere.15 In a study from South Africa, radiological 
features of OB were associated with a history of tuberculosis or severe pneumonia.13 Plain 
chest radiography is insensitive for small airways disease: definitive diagnosis usually requires 
HRCT,12 which is rarely available in low-income settings. Bronchiectasis is also a well-
recognised and irreversible cause of chronic lung disease among CWHIV, and can occur as a 
sequela of lymphoid interstitial pneumonitis, of recurrent pulmonary infections including 
tuberculosis and possibly of HIV infection itself.16  
 
Reports of paediatric HIV-associated chronic lung disease come mainly from low-income 
settings. This may be due to a higher prevalence of risk factors, including recurrent pulmonary 
infections in early life, delayed ART initiation, household air pollution, malnutrition and 
stunting.17 Malnutrition during the first year of life may be associated with decreased lung 
function at one year of age and stunting is a marker of delayed somatic growth; therefore, it is 
possible that stunted children may have smaller lungs and reduced lung volume.18    
 
Importantly, lung impairments and decreased lung function in childhood track through adult 
life and therefore pulmonary insults in childhood not only prevent an individual from reaching 
full potential lung potential but also increase risk of chronic lung disease in adult life (Figure 
2A).19-20 A South African study showed that lung function tracked over two years in 
adolescents with HIV who were well established on ART, and early life pulmonary 
tuberculosis or hospitalisation for lower respiratory tract infections was associated with 
reduced lung function.10    
 
Availability of diagnostic modalities for chronic lung disease such as spirometry and HRCT in 
low-income settings is limited and therefore chronic respiratory symptoms are frequently 
empirically treated with repeated antibiotics and anti-tuberculosis therapy in high HIV 
prevalence settings where tuberculosis is common. The pathogenesis of HIV-associated 
chronic lung disease is poorly understood, and without specific management guidelines. 
However, prevention of pulmonary infections by ensuring routine vaccinations including 
pneumococcal conjugate vaccine,21 annual influenza vaccination, early ART initiation, 
continued co-trimoxazole prophylaxis and use on isoniazid prophylactic therapy, avoidance of 
exposure to tobacco smoke and indoor air pollution and optimising nutrition may mitigate the 





Cardiovascular disease  
Recent studies from low-income countries have reported a high burden of HIV-associated 
cardiac abnormalities in CWHIV taking ART, with wide prevalence estimates between 14% 
to 89%, likely reflecting differences in selection of participants and measurements.22-24 The 
spectrum of abnormalities include left ventricular (LV) systolic and diastolic dysfunction, LV 
hypertrophy, left atrial dilatation, isolated right ventricular (RV) dilatation, conduction 
abnormalities and in some cases pericardial thickening or effusion (Figure 1B and C).23-25 In a 
South African cohort of adolescents with HIV, RV dysfunction was the most common form of 
cardiopulmonary dysfunction; cardiopulmonary dysfunction was associated with lower body 
mass index (BMI), height and past pulmonary tuberculosis.26 Notably, in most studies, children 
were pauci-symptomatic. A prospective study in Zimbabwean CWHIV on ART reported the 
incidence of left and right echocardiographic abnormalities as 3.52 and 5.64 per 100 person-
years, respectively.27 This study also found that most abnormalities persisted at 18 months but 
either asymptomatic or without worsening symptoms.27   
 
Much less attention has been given to assessment of vascular disease in CWHIV, although 
there is evidence from high-income countries that HIV and ART, particularly protease-
inhibitor-based regimens, are associated with subclinical atherosclerosis even in younger 
individuals.28 A recent South African study  reported an increased risk of endothelial 
dysfunction in adolescents with PHIV compared to their age-matched HIV-negative peers.29  
Traditional risk factors for cardiovascular disease including age, hypertension, smoking, lipid 
abnormalities do not play a significant role in this age-group and HIV and/or ART may thus 
play a much more significant role in the pathogenesis of vascular disease.  
 
The natural history and clinical significance of cardiac and vascular abnormalities is not clear. 
In contrast to findings from SSA, a study from the United States reported a decline in rates of 
cardiomyopathy in the era of ART.30 The underlying mechanistic pathways are not understood 
and the cardiac and vascular abnormalities reported may reflect impairment acquired prior to 
ART initiation. Surveillance and studies to investigate pathogenesis and progression are needed 
to understand whether these abnormalities are likely to result in an increased risk of premature 







Renal and metabolic disease  
Microalbuminuria is an early marker of glomerular injury and predicts further proteinuria 
development. Two studies from Tanzania and South Africa reported a variable prevalence of 
20.4% and 8.5% respectively for microalbuminuria in CWHIV.31,32 The children in the 
Tanzanian study were younger and more immunosuppressed, and microalbuminuria was 
strongly associated with immunosuppression, as well as haematuria.31 Notably, carriage of G1 
and G2 apolipoprotein-L1 (APOL1) gene variants is common in Africans and is associated 
with an increased odds of early renal disease, with HIV infection significantly augmenting 
risk.33  
 
Tenofovir disproxil fumarate (TDF) is associated with an adverse effect on renal function. TDF 
is associated with wasting of low molecular weight proteins, phosphate and glucose and 
although slowly progressive, chronic kidney disease in uncommon.34 Hyperphosphaturia 
secondary to tubular dysfunction can disturb renal-bone metabolic regulation, leading to 
progressive bone loss and hypophosphataemic osteomalacia, as observed in Fanconi 
syndrome.34  
 
Older ART drugs such as stavudine, didanosine and early generation protease inhibitors were 
associated with abnormal fat distribution (lipo-dystrophy or –atrophy). While newer ART 
regimens currently in use are less toxic, there is little improvement in those with established 
abnormalities following switching to newer, less toxic ART.35 ART is also associated with 
dyslipidaemia and insulin resistance; however, data are sparse for CWHIV in SSA. A study 
from South Africa of paediatric HIV clinic attendees currently taking either a 
lopinavir/ritonavir or efavirenz based ART regimen (and with 90% having taken stavudine 
previously) reported a 10% prevalence of insulin resistance using the Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR) index, and similar prevalence of 
dyslipidaemias.36 Overall, 40% had either insulin resistance or at least one lipid abnormality. 
The adjusted mean LDL cholesterol increased by 0.24mmol/l for each year of cumulative 
lopinavir/ritonavir exposure. Notably, the median BMI of participants was only 15kg/m2. In a 
trial comparing three different nucleoside reverse transcriptase inhibitor based regimens in 
children starting ART in Uganda, HOMA-IR increased significantly in all three arms 48 weeks 
after ART initiation, and correlated with monocyte activation.37 Similarly, in another study, 
abacavir was associated with increased HOMA-IR in adolescents.38 While the long-term 




resistance, dyslipidaemias and abnormal fat distribution are recognised risk factors for 
cardiovascular disease, hence monitoring is required. Switching to newer protease inhibitors 
such as atazanavir or darunavir in children taking lopinavir may improve lipid profiles.39  
 
Musculoskeletal disease  
HIV infection is associated with growth failure, manifesting as stunting (impaired linear 
growth) and pubertal delay with pubertal onset delayed by up to a year.40-41 Stunting is more 
profound among CWHIV in low-income than those in high-income settings, likely reflecting 
higher background rates of undernutrition and intercurrent infections.42   
 
Impaired growth may have a deleterious effect on musculoskeletal development and health 
across the life-course. Puberty is a critical period for musculoskeletal development and bone 
mass accrual. After cessation of linear growth and skeletal maturation, bone mass reaches a 
peak (peak bone mass [PBM]),43 after which bone mass declines at varying rates through 
adulthood (Figure 2B). PBM accounts for 60% of lifetime osteoporosis risk,44 with a 10% 
decrease in PBM doubling adult fracture risk.45 Pubertal delay predicts lower adult bone mass 
and increases future osteoporotic fracture risk.46 A systematic review of 32 studies found an 
increased prevalence of low bone density in CWHIV, and HIV appears to be associated with 
decreased bone accrual throughout childhood and adolescence.47 The majority of the studies 
were however from high-income settings and varied with respect to comparison groups, 
methods of measurement and adjustment for body size or growth retardation. A recent study 
from Zimbabwe showed reduced size-adjusted (Z-Score ≤ -2.0) lumbar spine  total-body-less 
head bone density measurements  in 15% and 13% of CWHIV aged 8 to 16 years taking ART.48  
Notably, this study used ‘gold-standard’ size adjustment methods for analysing dual X-ray 
absorptiometry scans which, if ignored, underestimate bone density in stunted children.49  
 
Certain ART drugs such as TDF may cause accelerated bone loss, likely aggravated by both 
low body mass and vitamin D deficiency.34 While studies have reported an association of TDF  
with lower bone density in CWHIV, this association may not be sustained longterm and 
longitudinal studies from SSA are needed to determine the impact of TDF on bone health in 
children.34,48,50 Additional factors, prevalent among CWHIV, can further compromise bone 
health, including low muscle mass, poor nutrition, inadequate dietary calcium, vitamin D 
deficiency and the HIV-associated pro-inflammatory milieu.51-53 Muscle strength and bone 




and strength.54 HIV infection and consequent ill-health may reduce physical activity levels, 
impairing muscle strength (Figure 2C) and skeletal impact loading, and thus bone 
development.55  
 
Although catch-up growth occurs after ART initiation, children who have more profound 
stunting and begin ART in later childhood have a delayed “growth spurt” and are typically 
unable to achieve their height potential.42,56,57 Age at ART initiation is an important predictor 
of bone density. In the Zimbabwe study, CWHIV starting ART after the age of eight years had, 
on average, at least a one standard deviation lower size-adjusted lumbar spine bone density.48  
This level of bone density reduction doubles fracture risk in adults.58 Given the late average 
age at ART initiation of CWHIV in SSA, these findings are concerning.6  
 
Developmental delay, neurocognitive disease and mental health   
In the pre-ART era, severe neurodevelopmental delay and HIV encephalopathy were common 
in CWHIV; the prevalence of HIV-associated neurocognitive impairment has declined in the 
ART era. Early ART initiation and viral suppression in infancy improves neurocognitive 
outcomes.59 However, CWHIV who start ART outside early infancy can experience subtle to 
severe neurocognitive deficits. In a prospective study of children aged 5-11 years from four 
SSA countries that compared neuropsychological outcomes in those with HIV with those who 
were HIV-exposed, uninfected and those who were HIV-unexposed, CWHIV performed worse 
in all cognitive domains than the other two groups. More than 95% of CWHIV had a suppressed 
HIV viral load and good immunological status (CD4% ≥25%), but only 1% started ART in the 
first six months of life.60     
 
An MRI study found that white matter (WM) structural abnormalities occur very early after 
birth, and even ART initiation by eight weeks of age may be too late to prevent HIV-associated 
WM abnormalities in the central nervous system.61 Second line ART, a high HIV viral load, 
low CD4 counts and poor cognitive function were associated with poor WM integrity measured 
by diffuse tensor imaging in CWHIV in a South African study.62 A recent meta-analysis 
demonstrated an association between HIV infection in children and adolescents and 
neurocognitive impairment, mainly in the domains of working memory, executive function and 
processing.63 There was also some evidence of deficits in visual memory and visual-spatial 
ability. Geographic bias was notable with only a third of studies coming from SSA. The causes 




ongoing viral replication in the central nervous system (CNS) and neuroinflammation, 
irreversible CNS injury prior to ART, neurotoxic effects of ART; and may be compounded by 
socioeconomic and psychosocial factors.64 Children with neurocognitive impairment may 
appear asymptomatic with deficits missed by routine testing. There is a lack of context-specific 
and culturally validated screening tools or standardised definitions. One study in South Africa 
has recently validated a youth International HIV Dementia Screen.65  
 
Several studies report a high prevalence of mental health disorders among children and 
adolescents with HIV. A large Ugandan study that recruited more than 1300 children and 
adolescents with HIV reported a prevalence of 17% of any psychiatric disorder and a 10% 
prevalence of a behavioural disorder most commonly attention deficit hyperactivity disorder. 
These disorders were more common in adolescents than in children and commonly occurred 
concurrently.66 Similarly a study from South Africa reported that adolescents with HIV had 
poorer functional competence, self-concept and motivation and higher levels of depression, 
disruptive behaviour, attention-deficit hyperactivity disorder symptoms and clinically 
significant anger, compared to their HIV-negative peers.67 CWHIV face recurrent and 
cumulative psychosocial stressors that differ from other chronic childhood illnesses such as 
stigma and discrimination, responsibility for welfare of siblings or other ill family members, 
illness and the death of their parents and unstable guardianship. This may hamper development 
of protective mechanisms and leave children psychologically vulnerable and ill-equipped for 
coping with challenges, likely increasing the risk of development of mental disorders.67-69 It is 
possible that the neuropathological effects of HIV infection may augment risk.70 Mental health 
disorders impact adherence to ART and are associated with an impaired quality of life, yet they 
typically receive little attention in the face of physical health concerns. 
 
Malignancy 
As CWHIV reach adolescence and become sexually active, they are at risk of acquiring Human 
Papilloma Virus (HPV) infection, with certain subtypes (e.g. 16 and 18) known to cause 
cervical cancer. The risk may be higher in those with HIV; in an Asian study, perinatally-
infected adolescent females had a higher prevalence of  high-risk HPV and abnormal cervical 
cytology than uninfected adolescents,  after adjusting for age, sexual history and pregnancy. 71  
The quadrivalent HPV vaccine was safe and highly immunogenic  in boys and girls with HIV 
in a study from Kenya.72 WHO recommends a 3-dose series (0,1-2, 6 months) for females with 




old), following studies that showed lower antibody titres post HPV vaccination in HIV-infected 
compared to uninfected women.72,73 HIV testing prior to vaccination is not recommended 
which may mean that adolescents with HIV may miss the 3rd dose if vaccination programmes 
are implemented in schools.  
 
CWHIV with advanced immunosuppression prior to ART or who started ART at an older age 
have an increased risk of cancer compared to those with modest immunosuppression or who 
began ART in infancy.74 Reliable cancer incidence estimates in CWHIV are difficult to 
generate as many cancer registries do not report HIV status, and cancer incidence rates vary 
according to  regions and study periods. Linked data from five paediatric ART programmes 
and four paediatric oncology units in South Africa showed an overall incidence rate of cancer 
of 82/100,000 person-years. The most common cancers were Kaposi’s Sarcoma (KS) and non-
Hodgkin’s lymphoma (NHL), with incidence rates of 34 and 31/100 000 person- years 
respectively.75 The risk of developing cancer was reduced by 70% for those children on ART, 
and risk increased with age at enrolment and immunodeficiency at enrolment.  The risk of KS 
is limited to CWHIV in or from SSA. A study reported  KS incidence rates of 81, 86, 11 per 
100 000 person-years in children from SSA living in Europe, Eastern Africa and Southern 
Africa respectively, with no KS cases in children of non-SSA origin in Europe and in Asia.76  
Data from Malawi suggest that KS rates are increasing. The average annual number of new KS 
diagnoses was 18 cases per year from 2006-2010, increasing to 25 cases per year from 2011 to 
2015, despite improved access to ART.77 Although this could be explained by increased 
awareness and detection, it is also possible that the cumulative risk of malignancy increases 
with age even in the era of ART. An older study from the United States that followed children 
for ten years showed that whilst the incidence of KS and NHL decreased in the ART era, the 
risk of developing non-AIDS-defining cancers did not.78 This highlights the need for continued 
monitoring of children growing up with HIV. Access to comprehensive cancer services 
remains limited in most low-income settings and mortality remains high. 
 
Other comorbidities 
In addition, there are other comorbidities that are common among CWHIV such as visual and 
hearing impairment and dental disease even in the ART era.79-82 Skin disease is severe and 
atypical, responds less well to treatment, and relapse more frequently compared with HIV-
uninfected children. Although incidence has declined in the ART era, HIV-related skin 




workers caring for CWHIV. ART is associated with risk of drug reactions and immune 
reconstitution inflammatory syndrome skin disease (unmasking of new skin disease or 
paradoxical worsening of existing dermatological conditions).83 These conditions receive little 
attention as they may not be “life-threatening” but lead to complications and disability, reduced 
quality of life and frequent clinic attendances placing an additional burden on health services.  
 
Pathogenesis of chronic co-morbidities 
The mechanisms underlying the comorbidities described in association with PHIV infection 
are largely unknown. Some of the underlying mechanisms may be shared with those seen in 
adult HIV infection, whilst others may be unique to the paediatric age-group, in keeping with 
the distinct clinical features observed in this age-group. Pathogenic mechanisms may also 
differ between populations in high and low-income settings. 
 
In adults, the development of HIV-associated comorbidities is thought to be related to levels 
of persistent immune activation, predominantly reflecting activation of monocytes and 
macrophages, rather than T-cell activation.84 A number of biomarkers have been described, 
largely in cross-sectional studies, that associate with adult comorbidities.85 These include 
inflammatory markers such as Interleukin 6, soluble tumour necrosis factor receptors I and II 
(sTNFR-I and sTNFR-2), Interferon-inducible Protein 10 (IP10) and high sensitivity C-
reactive protein, markers of monocyte activation such as soluble CD14 and CD163, markers 
of indoleamine 2,3-dioxygenase-1 activity, markers of coagulation risk, particularly D-dimer 
levels, and markers of gut barrier dysfunction, Zonulin and intestinal fatty acid binding protein. 
In longitudinal studies, rising levels of these biomarkers better predicted the development of 
NADIs than a single value at recruitment.86 These findings suggest that impaired gut barrier 
function leads to the translocation of microbial products from the gut into the circulation, where 
they activate monocytes and macrophages, initiating a cycle of chronic inflammation.85 This 
appears to be related to the activation of a specific subset of inflammatory monocytes which 
express Tissue Factor: these can secrete high levels of pro-inflammatory cytokines as well as 
trigger the coagulation cascade, so are particularly implicated in HIV-associated 
coagulopathy.87  
 
Additional contributing factors to inflammation include vitamin D deficiency and 




activation levels in individuals with HIV, potentially mediated through its immunomodulatory 
effects on populations of monocytes and macrophages, dendritic cells, and B and T 
lymphocytes.89 A trial of vitamin D supplementation in deficient CWHIV well-controlled on 
ART, led to significant reductions in both T-cell and monocyte activation.90   
 
The relationship between comorbidities and CMV infection is difficult to disentangle, as 
virtually all individuals with HIV have CMV co-infection: however, in the few studies that 
include CMV-negative HIV-infected subjects for comparison, HIV/CMV co-infected people 
have higher plasma levels of IP-10, TNF-R2 and D-dimer,91 and have an increased risk of 
NADIs, particularly cardiovascular and cerebrovascular disease.92 In cohort studies, 
associations have been described between inflammatory markers, the development of 
comorbidities and levels of CMV IgG,93,94 and CMV-specific T-cells,95 implying that 
subclinical CMV reactivation/replication is reflected in elevated immune responses: however, 
it is important to control for ageing in these studies.96 For CWHIV in low-income settings, 
especially when HIV diagnosis and ART initiation is delayed, it is likely that primary CMV 
infection occurs in infancy at a time of uncontrolled HIV replication. African children acquire 
CMV infection early in life, primarily through breastmilk exposure: in studies in The Gambia, 
85% of infants had acquired CMV by 12 months of age, reaching 100% by 18 months.97 Thus, 
their situation is distinct from that of adults who mainly acquire HIV after CMV infection and 
would already have generated immune responses leading to long-term viral control. Therefore, 
CMV reactivation or reinfection may occur more frequently in late-diagnosed children with 
PHIV and could make a greater contribution to the pathogenesis of comorbidities. A recent 
study in Zimbabwe reported unexpectedly high levels of CMV viraemia in older CWHIV.98  
The detection of CMV DNA in plasma was associated with two of the major comorbidities 
described in older children with PHIV, chronic lung disease and stunting. Further studies are 
needed to determine whether similar findings are seen in other settings and if CMV DNA-
aemia represents reactivation of latent infection or reinfection with new viral strains.  
 
The other key difference between children and adults is the greater potential for lymphopoiesis 
with enhanced thymic and bone marrow activity: paediatric slow progressors are characterised 
by what was described as “supranormal” thymic activity.99 However, thymic infection leading 
to impaired function can occur in a proportion of CWHIV, which is associated with 
significantly more rapid disease progression.100 Several studies suggest that children with 




epigenetic features of ageing,103 and accumulation of senescent (CD28- CD57+) and exhausted 
(PD-1+) T-cells.102 In these subjects there are also features of thymic dysfunction,102 which 
could potentially indicate HIV infection of the thymus, leading to an inadequate response to T-
cell turnover driven by immune activation.  
 
In summary, comorbidities in CWHIV are likely to reflect persistent immune activation and 
premature aging of the immune system, potentially driven in low income settings by early-life 
infection with CMV and exacerbated by vitamin D deficiency (Figure 3). Interventions aimed 
at reducing inflammation, CMV suppression and/or vitamin D supplementation may have 
potential for control or even reversal of comorbidities and merit further study. 
 
Recommendations for Policy and Research  
While the access to paediatric ART has increased dramatically in the past decade, coverage in 
children lags behind that in adults with about 54% of CWHIV globally accessing treatment in 
2018 compared to 62% of adults.104 Timely diagnosis and treatment of HIV infection in 
children remains a critical priority.  
 
In SSA, there is a large cohort of CWHIV entering adolescence and adulthood that has had 
delayed ART initiation, and are at increased risk of multi-system impairments and earlier onset 
of comorbidities that are usually associated with ageing. HIV care has to date mainly focused 
on delivery of and sustaining adherence to ART and there is an underappreciation of the burden 
of multisystem HIV-associated comorbidities among children. In addition, complex clinical 
issues place heavy demands on already overstretched health-care systems, and optimum 
screening and management strategies are not well defined. In response to this, the WHO 
convened two scoping meetings in 2014 and in 2019 to review available data and policies on 
management of major HIV-associated comorbidities as well as evidence gaps in clinical 
management and programming.  
 
Comprehensive HIV care should include diagnosis and management of comorbidities and 
consequent disability. The Panel outlines suggestions for interventions and research priorities 
aimed at addressing HIV-associated comorbidities in children. In Africa, dedicated paediatric 
and adolescent HIV care services are the exception rather than the rule. Provision of 




care settings, integrate within existing HIV and maternal, newborn and child health platforms 
and consider the physiological and psychosocial changes through childhood.  Importantly, 
inclusion of guardians, teachers and communities as equal partners will be critical to optimally 
support CWHIV achieve their full potential.  
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  Panel: Addressing HIV-associated comorbidities in children and adolescents 
 
Research priorities  




Diagnosis and screening 
• Standard definitions of comorbidities based on population-specific normative ranges  
• When to start and frequency of screening  
• Age- and culturally appropriate screening tools for mental health and neurocognitive 
disease  
 
Interventions for prevention and treatment 
• Preventive and therapeutic drugs: e.g. antibiotics, antivirals, anti-inflammatory drugs, 
Vitamin D 
• Feasible and effective educational and mental health interventions  
• Interactions of drugs used for prevention/treatment with antiretroviral therapy 
 
Service delivery  
• How to integrate diagnosis and management of HIV-associated comorbidities within HIV 
services and/or maternal, newborn and child health platforms 
 
Components of comprehensive HIV care 
• Earlier initiation of antiretroviral treatment to prevent complications 
• Monitoring growth, musculoskeletal and neurocognitive development   
• Screening for cardiac, lung and renal disease  
• Assessment of psychosocial status (schooling, guardianship) and mental health 
• Management of common mental health disorders and psychosocial support   
• Isoniazid and cotrimoxazole prophylaxis  
• Optimal nutrition  
• Catch up or re-vaccination according to WHO guidelines e.g. pneumococcal and influenza 
vaccination  
• Human papillomavirus vaccination for adolescents 
• Cervical cancer screening after sexual debut 
• Referral to clinical specialties for management  
• Liaison with disability and rehabilitation services  
• School-based programmes to provide educational support 
• Leverage existing early child development platforms for supporting CWHIV 










Despite antiretroviral therapy, longstanding HIV infection in children is associated with 
multisystem chronic comorbidities, particularly in sub-Saharan Africa where HIV treatment 
initiation is often delayed and occurs much later in childhood than in high-income settings 
Chronic morbidities in children with HIV are driven by underlying dysregulated immune 
activation associated with HIV infection, or are a sequelae of infections and/or HIV treatment 
HIV programmes have predominantly focused on delivery of antiretroviral therapy and there 
has been much less attention paid to diagnosis and management of chronic comorbidities 
Validated tools for screening and diagnosis and evidence-based interventions  for prevention 
and treatment of comorbidities need to be developed 
As well as earlier initiation of antiretroviral therapy, HIV care programmes need to identify 
an address the additional health needs of children with chronic complications including 
educational support, rehabilitation, nutrition, psychosocial and mental health support, if 








Figure 1: Clinical comorbidities associated with HIV infection in children and 
adolescents   
A) High resolution computed tomography scan showing bilateral “black and white” lung 
(mosaic attenuation pattern) with decrease in the number and calibre of vessels (arrow). 
There is also atelectasis on the right and bronchiectasis.   
 
B) Parasternal long axis view (i)) and Apical 4-chamber view (ii) of a 12-year-old female 
with dilated right ventricle (RV), left ventricle (LV), right atrium (RA) and left atrium (LA) 
and pericardial effusion (PE).  
 
 
Figure 2: Hypothesised effect of HIV infection on respiratory function (adapted from 
reference 20) (A), bone mass (adapted from reference 47) (B) and muscle strength (C) 
across the life-course  
 
 
Figure 3: Pathogenesis of HIV-associated comorbidities 
 
 
 
 
  
